RNA-derived medicines: a review of the research trends and developments

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

RNA-derived medicines: a review of the research trends and developments

Sponsored by

Logo 22.07.22.png
Coronavirus RNA strand. Medical illustration. 3D rendering

CAS considers how the emerging field of RNA therapeutics highlights trends in targets, chemical modifications, and new delivery systems that increase stability of RNA

In the last decade, there has been an encouraging shift in research, clinical development, and commercial activity to exploit the many biological roles of ribonucleic acid (RNA) for use in medicine. RNA technology provides an innovative approach to developing drugs against difficult or challenging therapeutic targets, holding potential across many diseases ranging from the largest global health challenges to extremely rare diseases.

However, RNA medicine has faced many challenges: RNA molecules are relatively unstable and transient, the limited translation into cellular protein expression can hinder efficacy, and foreign RNA molecules often trigger immunogenicity. Furthermore, the delivery of RNA molecules can be a challenge due to their relatively large size and high electric charge.

Some of these practical problems can be mitigated by chemically modifying the RNA, providing the opportunity to develop therapeutics that are more stable, effective, and tolerable for patients. The recent success of mRNA vaccines against COVID-19 and the approval of new RNA-based drugs has provided new momentum to the field, building on the key milestones and achievements of the last 60 years. Advances in our understanding of RNA structure and function, combined with a robust production pipeline, have substantially increased the capacity to develop clinically effective RNA-related applications.

In this white paper, CAS used data from the CAS Content CollectionTM—the largest human-curated collection of published scientific knowledge—to review publication trends in RNA research, the application of RNA in medicine and the use of chemical modifications and nanotechnology to improve the delivery and efficacy of RNA pharmaceuticals. The white paper focuses on chemical modifications to the nucleic acid base, backbone, and sugar molecules to increase RNA stability, along with the new delivery systems that are critical to the success of RNA medicine.

Click here to access CAS’s white paper – “RNA-derived medicines: a review of the research trends and developments”

Click here to access CAS’s content hub on Managing IP

more from across site and SHARED ros bottom lb

More from across our site

A seminal decision concerning second medical use patents and questions over confidentiality were among the top talking points this fortnight
Managing IP considers some of the key themes from the 2025 Annual Meeting and offers some tips for London 2026
A comparison of the 2024 and 2025 editions of the Managing IP EMEA Awards reveals the firms and companies that have been dominating Europe’s IP market year after year
Tuesday's coverage includes BD tips for aspiring partners, and a foray into the world of SEPs
Exclusive data reveals law firms are failing to go above and beyond for their corporate clients, with in-house counsel saying advisers should consider more transparent billing processes
Arty Rajendra and Gary Moss discuss why ‘thorough and intense’ preparation, plus the odd glass of wine, led to a record FRAND victory for their client
Monday’s coverage includes news of a potentially 'game-changing' trademark development in China and how practitioners are using AI
Managing IP gives a taster of the numbers behind this year’s IP STARS trademark rankings, and looks back at our 2025 award winners
Updates from IP offices, the shifting requirements of in-house counsel, and news of London 2026 were among major talking points on Sunday
Etienne Sanz de Acedo discusses the association’s three-year plan, what he is looking forward to in San Diego, and why London came calling for 2026
Gift this article